Sign in
Taking people in United StatesNo phase

Studies the heart in people with Friedreich's ataxia

Observes heart changes in people with Friedreich's ataxia using heart scans and tests.

Key facts

Who runs it
Weill Medical College of Cornell University
Where
New York, United StatesSee the site
Trial code
Registry title
Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)
Status
Recruiting
People taking part
100 people, planned
Started
15 Jan 2015
Expected to end
Aug 2027
Type of study
Observational, 2 groups
Treatments tested
  • Cardiac magnetic resonance imaging (CMR)
  • Exercise-stress test
  • Echocardiogram (ECHO)
  • Cardiac-related blood studies
Record updated
29 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 12 to 50 with Friedreich's ataxia, and healthy volunteers aged 12 to 30 as a comparison group. It studies how the disease affects the heart.

Age
People with Friedreich's ataxia: 12 to 50 years. Healthy volunteers: 12 to 30 years.
Sex
Men and women can join.
Disease stage
A definite diagnosis of Friedreich's ataxia, based on symptoms and genetic testing. Heart pumping strength (left ventricle ejection fraction) on ECHO must be above 35%.
Earlier treatment
Anyone who received an investigational drug in the last 30 days or 5 half-lives, whichever is longer, cannot join.
Biomarker or test result
Genetic confirmation of Friedreich's ataxia is needed.

Main reasons for not taking part

  • Signs or symptoms of heart failure
  • Moderate to severe heart rhythm problems, or a history of angina
  • Pacemaker, defibrillator or other device that blocks MRI
  • Dialysis, severe kidney disease, or acute kidney injury
  • Type 1 or Type 2 diabetes, or pregnancy

The registry criteria, word for word

Show all 33 criteriaShow less

Other criteria

  • Friedreich's Ataxia - Inclusion Criteria:
  • Males and females, age 12 to 50
  • Willing and able to provide informed consent (adolescents will need to provide assent and a parent to provide consent)
  • Definitive diagnosis of FRDA, based on clinical phenotype and genotype
  • Left ventricle ejection fraction measured by ECHO of >35% (If results of an ECHO are not available for a potential subject, then an ECHO will first be performed and subjects with an LVEF <35% will not be required to perform the CPET); Friedreich's Ataxia - Exclusion Criteria:
  • Signs and symptoms of cardiac failure
  • Moderate to severe atrial or ventricular arrythmias
  • History of angina pectoris
  • Implanted pacemaker and/ or defibrillator or any other device that would preclude MRI assessment
  • Any form of dialysis; Severe or end-stage CKD (CKD 4 or 5, eGFR < 30 ml/min/1.73 m2) without dialysis; eGFR 30 to 40 ml/min/1.73 m2 without dialysis; Acute kidney injury (If a recent assessment is not available, then a blood test to assess kidney function will be performed prior to cardiac MRI)
  • Females who are pregnant
  • Receipt of an investigational drug within 30 days or 5 half-lives, whichever is longer, prior to screening, or active enrollment in an investigational medication or device study
  • Unable to undergo cardiac MRI with gadolinium contrast or claustrophobia
  • Clinical history or evidence of Type 1 or Type 2 Diabetes mellitus
  • Any condition, disorder, or abnormal laboratory test findings at screening which, in the judgment of the investigator, would interfere with the individual's ability to comply with all study requirements, or would require the administration of treatment during the study that could potentially affect the interpretation of the study data, or would place the individual at an unacceptable risk by his/ her participation in the study; Normal controls - Inclusion Criteria:
  • Males and females, age 12 to 30
  • Willing and able to provide informed consent (Adolescents will need to provide assent and a parent to provide consent)
  • Matched age, gender and ethnicity to the FRDA group
  • Capable of undergoing the various modalities of cardiac assessment
  • Left ventricle ejection fraction measured by ECHO of >35% (If results of an ECHO are not available for a potential subject, then an ECHO will first be performed and subjects with an LVEF <35% will be withdrawn from the study); Normal controls - Exclusion Criteria:
  • Individuals not deemed in good overall health by the investigator will not be accepted into the study
  • Signs and symptoms of cardiac failure
  • Moderate to severe atrial or ventricular arrhythmias
  • History of angina pectoris
  • Implanted pacemaker and/ or defibrillator or any other device that would preclude MRI assessment
  • Any form of dialysis; Severe or end-stage CKD (CKD 4 or 5, eGFR < 30 ml/min/1.73 m2) without dialysis; eGFR 30 to 40 ml/min/1.73 m2 without dialysis; Acute kidney injury (If a recent assessment is not available, then a blood test to assess kidney function will be performed prior to cardiac MRI)
  • Females who are pregnant or lactating
  • Receipt of an investigational drug within 30 days or 5 half-lives, whichever is longer, prior to screening, or active enrollment in an investigational medication or device study
  • Unable to sit with back support
  • Unable to undergo cardiac MRI with gadolinium contrast or claustrophobia
  • Unable to undergo exercise tests
  • Clinical history or evidence of Type 1 or Type 2 Diabetes mellitus
  • Any condition, disorder, or abnormal laboratory test findings at screening which, in the judgment of the investigator, would interfere with the individual's ability to comply with all study requirements, or would require the administration of treatment during the study that could potentially affect the interpretation of the study data, or would place the individual at an unacceptable risk by his/ her participation in the study

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 12 and 50 years old?

This trial is currently available in United States.

  • Weill Cornell MedicineNew York, United StatesContact: Niamh Savage, BSTaking people

About the trial

What the trial wants to find out

Friedreich's ataxia (FRDA) is an autosomal recessive disease characterized by loss of coordination and cardiomyopathy. It is the most common form of inherited ataxia with an incidence in 1/50,000 in the Caucasian population. FRDA is associated with progressive damage to the nervous system, resulting in symptoms ranging from gait disturbance to speech problems, as well as diabetes and heart disease. The heart disease manifests as cardiomyopathy, and is responsible for approximately 60% of deaths from FRDA. This study is designed to characterize the cardiac manifestations of the disease using exercise, MRI, ECHO and serum parameters, in the context of the neurological disease. In addition, this study will demonstrate that corneal confocal microscopy (CCM) may also provide a biomarker for FRDA.

The 2 groups in the trial

  • Individuals diagnosed with FRDA

    Individuals diagnosed with FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies

    Treatment: Cardiac magnetic resonance imaging (CMR), Exercise-stress test, Echocardiogram (ECHO), and Cardiac-related blood studies

  • Healthy controls

    Individuals without FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies

    Treatment: Cardiac magnetic resonance imaging (CMR), Exercise-stress test, Echocardiogram (ECHO), and Cardiac-related blood studies

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)
Plain-language title
Studies the heart in people with Friedreich's ataxiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT02316314, who can take part
Record updated
29 July 2026